Source comparison
CJC-1295 Ipamorelin for Sleep Optimization: Protocol Comparison
Ipamorelin Only (nightly) 200–300 mcg before bed, 7 days/week Acute GH pulse triggering via ghrelin receptor agonism 12–18% above baseline Users wanting single-peptide simplicity or those sensitive to long-acting compounds Effective but requires daily administ
This comparison does not assign a generated winner or score.
- Ipamorelin Only (nightly)
- 200–300 mcg before bed, 7 days/week
- Acute GH pulse triggering via ghrelin receptor agonism
- 12–18% above baseline
- Users wanting single-peptide simplicity or those sensitive to long-acting compounds
- Effective but requires daily administration. GH pulses are strong but short-lived without GHRH amplification
- CJC-1295 + Ipamorelin (standard)
- Ipamorelin nightly + CJC-1295 2x/week
- Synergistic: GHRH amplification + ghrelin-driven pulse triggering
- 18–25% above baseline
- Most users seeking sustained sleep architecture improvement
- Gold standard combination. CJC-1295's half-life maintains elevated baseline GH while ipamorelin times acute pulses to nocturnal cycles
- CJC-1295 Only (maintenance)
- 1–2 mg twice weekly
- GHRH receptor-mediated baseline GH elevation
- 8–12% above baseline
- Maintenance phase after initial optimization or budget-conscious protocols
- Less pronounced effect than combination but sufficient for users who've already restored SWS architecture and want to maintain it
- Ipamorelin + MK-677 (oral GH secretagogue)
- Ipamorelin nightly + MK-677 10–25 mg daily
- Dual ghrelin receptor agonism (injectable + oral)
- 15–22% above baseline
- Users unable to source or store CJC-1295 reliably
- MK-677 elevates baseline ghrelin and increases appetite significantly. Effective but comes with water retention and potential insulin resistance at higher doses